Gray Belinda, Ackerman Michael J, Link Mark S, Lampert Rachel
Department of Cardiology, Royal Prince Alfred Hospital; Faculty of Medicine and Health University of Sydney; Centre for Cardiovascular Research, Centenary Institute, Sydney, NSW, Australia.
Mayo Clinic, Departments of Cardiovascular Medicine, Pediatric and Adolescent Medicine, and Molecular Pharmacology & Experimental Therapeutics; Divisions of Heart Rhythm Services and Pediatric Cardiology, Windland Smith Rice Genetic Heart Rhythm Clinic, Rochester, MN, USA.
Trends Cardiovasc Med. 2025 Feb;35(2):116-123. doi: 10.1016/j.tcm.2024.09.004. Epub 2024 Sep 30.
Historically, individuals with HCM have been restricted from vigorous competitive sports due to concerns for risk of sudden death. More recently, prospective data are emerging that individuals with HCM who participate in vigorous sports do not have increased arrhythmic risk compared to the less active, and series of athletes with HCM continuing to compete, while small, have not shown high risk. Guidelines are evolving, and while differences exist, all now recommend an individualized approach and shared decision-making for athletes with HCM wishing to return to play.
从历史上看，由于担心猝死风险，肥厚型心肌病（HCM）患者一直被限制参加剧烈的竞技运动。最近，有前瞻性数据表明，与运动较少的HCM患者相比，参加剧烈运动的HCM患者心律失常风险并未增加，并且虽然持续参赛的HCM运动员系列数量较少，但尚未显示出高风险。指南正在不断发展，尽管存在差异，但现在所有指南都建议对希望恢复比赛的HCM运动员采取个体化方法并共同决策。
